RedHill Biopharma Reports Results for the First Quarter of 2014 Key financial highlights include: A first profitable quarter, with net income of $3.4 million, primarily attributed to the $7 million upfront payment received from Salix Pharmaceuticals as part...

RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results 2013 Key Highlights Include: Strong cash position of over $34 million, as of February 2014, following two private placements in early 2014 and the exercise of warrants, including by directors...